Table of Contents
- What Is AOD-9604 and Where Did It Come From?
- How AOD-9604 Works on Fat Cells
- What the Clinical Trials Found
- Why the Larger Trial Told a Different Story
- How AOD-9604 Compares to GLP-1 Medications
- Does AOD-9604 Burn Belly Fat?
- How Long Does it Take to See Results from AOD-9604?
- Oral vs Injectable AOD-9604: Why the Form You Take Matters
- What are the Side Effects of AOD-9604?
- Where AOD-9604 Stands Today
- Where Your Peptide Comes from Matters Most
- Bottom Line: Is AOD-9604 Worth Paying Attention To?
Key Takeaways
- AOD-9604 is a C-terminal fragment of human growth hormone, built from the end of the molecule that controls fat metabolism.
- Metabolic Pharmaceuticals Ltd developed it in the 1990s as an obesity treatment, alongside research teams at Monash University in Melbourne, Australia.
- A 12-week trial found 2.6 kg of weight loss at 1 mg per day, compared with 0.8 kg on placebo.
- A larger 24-week trial in 536 subjects did not repeat that result, and the program ended in 2007.
- Across six trials, no serious adverse events were tied to taking it, and it did not raise IGF-1 or disturb blood sugar.
If you have been reading about the AOD-9604 peptide, you have probably seen the same promise repeated everywhere. It is the fragment of human growth hormone that handles fat, without the side effects that come with the full hormone.
That description is accurate. What most pages leave out is what happened when researchers tested it in people.
AOD-9604 has more human data behind it than almost any compound in the weight loss peptide research category. Six trials, roughly 900 participants, and a safety record that came back clean. Here is what those trials found, what they did not find, and where AOD-9604 sits today.
What Is AOD-9604 and Where Did It Come From?
AOD-9604 is a lab-made copy of one section of human growth hormone, with a single amino acid added for stability.
Growth hormone is a long chain of 191 amino acids. Different segments of that chain control different functions. The segment at the end, called the C-terminus, controls fat metabolism.
Researchers pulled out that segment, amino acids 176 to 191, and attached a tyrosine to the N-terminal end so the fragment would hold together better. That gave them a 16-amino-acid synthetic fragment, described in the early literature as a synthetic lipolytic domain.
Think of growth hormone as a keyring with several keys on it. Most of those keys open doors you may not want opened, like tissue growth and changes to blood sugar. AOD-9604 keeps the one key that handles fat and leaves the rest behind.
The company named it Anti-Obesity Drug 9604. That tells you exactly what they were building.
How AOD-9604 Works on Fat Cells
AOD-9604 works on fat cells through two actions that pull in the same direction.
The first is lipolysis, or fat breakdown. Your body stores fat as triglycerides inside adipose tissue. Lipolysis breaks those stores apart so they can be used for energy.
The second is slowing lipogenesis, which is fat storage. Feeding studies in preclinical models found the fragment altered both lipogenic and lipolytic activity in fat tissue.
How it manages the first part is more interesting than most sources let on. Preclinical work on lipid metabolism published in Endocrinology tested the fragment against the beta-3 adrenergic receptor, described there as the main fat-burning receptor on fat cells.
Chronic treatment lifted the repressed levels of that receptor in obese preclinical models back toward lean levels. More receptors meant greater lipolytic sensitivity.
The authors were clear on one point, though. AOD-9604 does not switch that receptor on directly. It raises how much of the receptor is present, which is a different mechanism. That distinction matters, because plenty of pages claim direct activation and the study they cite says otherwise.
The same work reported higher energy expenditure and fat oxidation, so more released fat gets burned rather than stored again. The metabolic actions are not mysterious, but they are indirect.
Why It Behaves Differently from Full Growth Hormone
The reason anyone bothered building a fragment is that full growth hormone comes with baggage.
Intact hGH raises a growth signal called IGF-1, which tells tissue throughout your body to grow. It can also push up insulin levels and lower your insulin sensitivity, so your body stops responding well to the insulin it makes. That drift is called insulin resistance, and it points toward the blood sugar problems behind diabetes.
So researchers went looking for those exact problems. Pooled safety data published in the Journal of Endocrinology and Metabolism covered six trials and tracked all three.
AOD-9604 came back clear. It did not raise IGF-1, and when participants drank a sugar solution so researchers could watch their response, their blood sugar handling held steady. The authors said it plainly: the fragment caused none of the side effects that come with full-length hGH.
That clean profile is why AOD-9604 comes up in metabolic syndrome discussions, though no trial has tested it for that use. For anyone comparing peptide therapy options, it stays the strongest point in its favor.
What the Clinical Trials Found
AOD-9604 went through 6 randomized, double-blind, placebo-controlled trials, with roughly 900 participants across the safety program. That is a lot of human testing for a research peptide. Most peptides you read about have a handful of small studies at best.
The efficacy picture came down to two trials.
| Earlier trial | Final trial | |
|---|---|---|
| Length | 12 weeks | 24 weeks |
| Dose | 1 mg per day | Not stated in the review |
| Result | 2.6 kg average weight loss vs 0.8 kg on placebo | No meaningful weight loss |
| Outcome | Promising enough to keep going | Program ended in 2007 |
A review in Current Cardiology Reviews recorded both outcomes and noted that development stopped after the 24-week trial in 536 subjects.
Here is the part that puts those numbers in context. The same review explains that the FDA looks for 5% weight loss beyond what placebo achieves before approving a drug for obesity treatment.
The gap between 2.6 kg and 0.8 kg is roughly 1.8 kg. For most people in those trials, that sits well short of the mark, even in the trial where the result held.
So the honest summary is this. AOD-9604 did something measurable to body weight. It just never did enough to clear the bar set for an approved obesity drug.
Why the Larger Trial Told a Different Story
Two details explain the gap between those trials, and almost nobody covers them.
The first is study design. A safety and metabolism review of AOD9604, co-authored by the developer, describes two oral phase 2b studies, one in 300 obese adults and one in 500. Weight loss showed up in the earlier trials but not in the last one, which added an intensive diet and regular physical activity regime.
When participants were already working hard on body recomposition, the peptide added little on top. Read plainly, that tells you something useful. AOD-9604 is not a replacement for diet and training.
The second detail is biology. The same review is candid that the mechanism is not fully understood, and describes the fragment as working partly by lifting the repressed levels of beta-3 receptors on fat cells. Raising a count only helps when there is a count to raise.
The Current Cardiology Reviews analysis explains why that matters less in people. Animal models carry beta-3 receptors in both white and brown fat. Humans carry them mainly in brown fat, and the amount of brown fat you have drops as you get older.
So a strategy with plenty of targets in a preclinical model has fewer to work with in a grown adult. That is a translation problem, not a sign the compound is unsafe.
How AOD-9604 Compares to GLP-1 Medications
Most people asking about AOD-9604 have already heard of GLP-1 drugs like semaglutide. The two work in completely different ways.
GLP-1 medications act on appetite. They slow how fast your stomach empties and change hunger signals, so you eat less without trying.
AOD-9604 does none of that. It does not suppress appetite like GLP-1 medications, and it does not affect gastric emptying, because it was built to act on fat cells rather than on digestion.
| AOD-9604 | GLP-1 medications | |
|---|---|---|
| Main action | Works on fat cells directly | Reduces appetite, slows digestion |
| Weight loss in trials | 2.6 kg over 12 weeks | 15% or more of body weight |
| Effect on lean mass | Not measured in published trials | Can cause lean mass reduction during weight loss |
| Approval status | Not yet approved | Approved for weight management |
Being straight about this matters. GLP-1 drugs produce far greater weight loss and have the evidence to back it. AOD-9604 is a much gentler tool, and it should not be sold as a swap for them.
Does AOD-9604 Burn Belly Fat?
No. There is no evidence that AOD-9604 targets fat in one area of your body over another.
Spot reduction does not happen with peptides, and it does not happen with exercise either. When you lose body fat, your body draws from stores across your whole frame, following patterns set largely by genetics.
Marketing pages often claim AOD-9604 goes after stubborn fat around the abdomen, hips, or thighs. That claim does not appear in any of the trial data.
What the research does support is a modest, whole-body shift in fat metabolism. The 2.6 kg figure was total body weight, not fat measured in one region. If a source promises area-specific results, read the rest of their claims carefully.
How Long Does it Take to See Results from AOD-9604?
The clearest answer comes from the trials: 12 weeks of daily dosing at 1 mg per day, taken orally.
That is more than most peptides can offer. Plenty have no human timeline at all, so you are guessing. Here you have a real number to plan around.
Over those 12 weeks, participants lost 2.6 kg compared with 0.8 kg on placebo, more than three times the change. The research describes AOD-9604 as supporting steady, moderate weight reduction rather than fast drops, which is how lasting fat loss tends to work anyway.
Oral vs Injectable AOD-9604: Why the Form You Take Matters
If needles put you off, this is one peptide where you have options. Most peptides do poorly by mouth. Your digestive tract breaks protein apart, so a swallowed peptide often gets treated like food and dismantled before it does anything. That is why so many come as injections.
AOD-9604 is an exception, which is why researchers built the trials around oral dosing. Both larger efficacy trials used it, and preclinical work found roughly 40% of an oral dose reached circulation. Injected AOD-9604 cleared the blood in about 3 minutes, while oral dosing delivered several times more total exposure.
Slower turned out to be better here. Oral absorption spreads out, so the peptide stays available longer instead of spiking and vanishing.
Formulation decides the rest, since salt form and protective carriers determine how much survives the trip. That is why oral versus injectable peptide delivery matters, and why two products with the same label can perform differently.
Working with an injectable instead? A peptide reconstitution calculator takes the guesswork out of mixing.
What are the Side Effects of AOD-9604?
This is where AOD-9604 looks better than most research peptides. Across six controlled trials, the pooled safety review found no withdrawals or serious adverse events connected to taking it. No anti-AOD9604 antibodies were detected in any patient tested for them. Tolerability was described as hard to tell apart from placebo.
Those trials also confirm no rise in IGF-1, which was the outcome researchers watched most closely given the growth hormone connection.
Injection site reactions are the most commonly mentioned mild side effect, though those reports come from clinic and user experience. The trials used oral and IV dosing, so this is not a trial finding.
Where AOD-9604 Stands Today
AOD-9604 no longer sits in Category 2, the FDA list flagging substances that may present significant safety risks in compounding. It appears instead on the agency's withdrawn peptide nominations list, covering substances pulled by the nominators rather than turned down by the FDA. Nobody argued the case and lost. The file was simply pulled.
AOD-9604 is not in the current advisory committee round, so it has no scheduled path onto the approved compounding list yet. It has not been ruled out either. The 2026 peptide compounding rules have opened up considerably since 2023, and this file is sitting still rather than closed.
Where Your Peptide Comes from Matters Most
Most of the safety conversation around AOD-9604 is really about where a vial came from.
The trials used material made to a known standard and tested before anyone took it. Much of what sells online is a different product wearing the same name. Anything labeled research use only sits outside that oversight, and independent testing across the gray market keeps finding vials that are under-dosed, degraded, or not what the label claims.
Trial data only tells you what to expect if what is in the vial matches what was tested. Three things to check before buying any peptide:
- A lot-specific certificate of analysis from an independent lab
- Identity and purity results, confirming the peptide is what the label says and how much is there
- Storage and shipping conditions, since peptides degrade with heat and time
Competitive athletes have one more reason to pause. AOD-9604 is named on the list of peptides banned in sport under WADA rules, so it will show up in testing however it was sourced.
Bottom Line: Is AOD-9604 Worth Paying Attention To?
AOD-9604 is one of the better-documented peptides in the fat metabolism space, with a gentle effect and an unusually clean safety record. Six controlled trials, roughly 900 participants, and no serious adverse events tied to taking it. It did not raise IGF-1 or disturb blood sugar either, which is more than most peptides can claim.
Keep expectations grounded on results. The fat loss was steady and moderate, and it worked best alongside diet and training rather than instead of them.
The practical limit today is access, since AOD-9604 sits outside the current compounding review rather than being ruled out.
If you are exploring peptides for fat support, treat AOD-9604 as a solid piece of the picture rather than the whole plan. Know what the research says, ask where your supply comes from, and let diet and training do their share.
Disclaimer: This article is for general information only and is not medical advice. AOD-9604 has been studied in several human trials with a reassuring safety record, though it has not been approved as a medicine. Talk with a licensed healthcare professional before starting any peptide or changing your treatment plan.
